Portfolio Company · Operating Co.

CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA

a portfolio company of

Status on record: Exited

PE Firm Index

Who owns CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA?

CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA is listed as an exited portfolio company of Latticework Capital Management on Latticework Capital Management's own portfolio page.

Company Snapshot

CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA is a pharmaceutical contract development and manufacturing organization company. Its owner on record, Latticework Capital Management, is a private equity firm. Latticework Capital Management lists 23 companies in the index, 6 of them in pharmaceutical contract development and manufacturing organization.

Sectorpharmaceutical contract development and manufacturing organization

Parent PE firmLatticework Capital Management

Ownership statusExited

WebsiteNot on record

About the owner

Latticework Capital Management

Strategy: Private equity, Control equity investments, Growth-oriented
Sectors: Healthcare, Healthcare providers, Pharmaceutical services
Companies in the index: 23

Latticework Capital Management is a private equity firm that makes control equity investments in lower-middle market healthcare companies.

Read the Latticework Capital Management profile

Questions about CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA

Who owns CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA?

CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA is listed as an exited portfolio company of Latticework Capital Management on Latticework Capital Management's own portfolio page.

What sector is CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA in?

CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA is in pharmaceutical contract development and manufacturing organization. Classified from the owner's portfolio label.

What else does Latticework Capital Management own in pharmaceutical contract development and manufacturing organization?

Latticework Capital Management lists 5 other pharmaceutical contract development and manufacturing organization companies in the index, including ACCELLENT, CHRONIC CARE SOLUTIONS, inReach Health, MEADOWS BEHAVIORAL HEALTHCARE and SCIENTIFIC PROTEIN LABORATORIES.

Sources

Latticework Capital Management
https://latticeworkcapital.com/portfolio/

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with CAMBRIDGE MAJOR LABORATORIES / AAI PHARMA and does not provide investment advice.

Other portfolio companies of Latticework Capital Management

6 of 22 shown

ACCELLENT

medical device industry

ACRS

American Veterinary Group

ATI PHYSICAL THERAPY

orthopedic rehabilitation provider

Beacon Behavioral Partners

CHRONIC CARE SOLUTIONS

diabetic patients

See the full Latticework Capital Management portfolio.

Other pharmaceutical contract development and manufacturing organization companies held by Latticework Capital Management

ACCELLENT CHRONIC CARE SOLUTIONS inReach Health MEADOWS BEHAVIORAL HEALTHCARE SCIENTIFIC PROTEIN LABORATORIES

Other pharmaceutical contract development and manufacturing organization portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Latticework Capital Management

Status: Exited

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.